AU2002214626A1 - Quaternary amines and related inhibitors of factor xa - Google Patents

Quaternary amines and related inhibitors of factor xa

Info

Publication number
AU2002214626A1
AU2002214626A1 AU2002214626A AU1462602A AU2002214626A1 AU 2002214626 A1 AU2002214626 A1 AU 2002214626A1 AU 2002214626 A AU2002214626 A AU 2002214626A AU 1462602 A AU1462602 A AU 1462602A AU 2002214626 A1 AU2002214626 A1 AU 2002214626A1
Authority
AU
Australia
Prior art keywords
factor
quaternary amines
related inhibitors
inhibitors
quaternary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214626A
Inventor
Liang Bao
Robert M. Scarborough Jr.
Penglie Zhang
Bing-Yan Zhu
Jingmei Fan Zuckett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Publication of AU2002214626A1 publication Critical patent/AU2002214626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
AU2002214626A 2000-09-29 2001-10-01 Quaternary amines and related inhibitors of factor xa Abandoned AU2002214626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23633000P 2000-09-29 2000-09-29
US60/236,330 2000-09-29
PCT/US2001/042352 WO2002026712A2 (en) 2000-09-29 2001-10-01 Quaternary amines and related inhibitors of factor xa

Publications (1)

Publication Number Publication Date
AU2002214626A1 true AU2002214626A1 (en) 2002-04-08

Family

ID=22889060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214626A Abandoned AU2002214626A1 (en) 2000-09-29 2001-10-01 Quaternary amines and related inhibitors of factor xa

Country Status (3)

Country Link
US (1) US20040067938A1 (en)
AU (1) AU2002214626A1 (en)
WO (1) WO2002026712A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
EP1542692B1 (en) 2002-05-22 2011-01-05 Amgen Inc. Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain
PL376372A1 (en) 2002-08-08 2005-12-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2541809A1 (en) * 2003-10-09 2005-04-21 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
WO2005077938A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
JP5640005B2 (en) 2008-07-14 2014-12-10 ギリアード サイエンシーズ, インコーポレイテッド Imidazosylpyridine compounds as HDAC and / or CDK inhibitors
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
MX2011001090A (en) 2008-07-28 2011-03-15 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds.
FR2942456B1 (en) 2009-02-25 2012-12-07 Sicma Aero Seat MODULE FOR AIRCRAFT CABIN AND ASSOCIATED AIRCRAFT CABIN.
CA2763786C (en) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
KR20120024722A (en) 2009-06-08 2012-03-14 길리애드 사이언시즈, 인코포레이티드 Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
EP2766360B1 (en) 2011-08-12 2017-07-12 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
AP2015008231A0 (en) 2012-09-07 2015-01-31 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
HUE049231T2 (en) 2014-07-22 2020-09-28 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CA3129131A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Charged ion channel blockers and methods for use
AU2020234961A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20210145164A (en) * 2019-03-11 2021-12-01 녹시온 테라퓨틱스 인코포레이티드 Ester Substituted Ion Channel Blockers and Methods of Use
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
MX2022001863A (en) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors.
US10842798B1 (en) 2019-11-06 2020-11-24 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4054586A4 (en) 2019-11-06 2023-11-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20220123058A (en) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition
MX2022008103A (en) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof.
KR20230022830A (en) 2020-03-11 2023-02-16 녹시온 테라퓨틱스 인코포레이티드 Charged ion channel blockers and methods of use
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3811006B2 (en) * 1997-12-19 2006-08-16 シエーリング アクチエンゲゼルシャフト Ortho-anthranilamide derivatives as anticoagulants
DE69829879T2 (en) * 1997-12-24 2006-03-02 Sanofi-Aventis Deutschland Gmbh INDOLE DERIVATIVES AS FACTOR XA INHIBITORS

Also Published As

Publication number Publication date
WO2002026712A3 (en) 2002-10-17
WO2002026712A2 (en) 2002-04-04
US20040067938A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2002214626A1 (en) Quaternary amines and related inhibitors of factor xa
HUP0203289A3 (en) Benzamides and related inhibitors of factor xa
AU2001249399A1 (en) Isoquinolone inhibitors of factor xa
ZA200306488B (en) Benzamides and related inhibitors of factor Xa.
AU5723500A (en) Inhibitors of factor xa
HK1061851A1 (en) Gyrase inhibitors and uses thereof
AU5158100A (en) Inhibitors of factor xa
AU5283900A (en) Inhibitors of factor xa
AU3857300A (en) Inhibitors of factor xa
HK1053984B (en) Gyrase inhibitors and uses thereof
AU2001236605A1 (en) Indole and benzimidazole inhibitors of factor xa
AU2001273040A1 (en) Factor xa inhibitors
IL156737A0 (en) Substituted amine derivatives and methods of use
GB0025782D0 (en) Use of inhibitors
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU5284000A (en) Inhibitors of factor xa
AU2001216218A1 (en) Heterocyclic analgesic compounds and method of use thereof
AU2001249397A1 (en) Oxindole inhibitors of factor xa
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001294824A1 (en) Piperazine based inhibitors of factor xa
AU2001281799A1 (en) Benzamide derivatives and their use as apob-100 and mtp inhibitors
AU2003299815A1 (en) Matriptase inhibitors and methods of use